Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 8/20 | 0.62 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 6/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | THPO | P40225 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881886 | 1.00 | BLM (0.62) | BLMTSHRNPSR1TDP1LMNA | |
| SCHEMBL29935536 | 1.00 | BLM (0.62) | BLMTSHRNPSR1TDP1LMNA | |
| SCHEMBL28135952 | 1.00 | BLM (0.62) | BLMTSHRNPSR1TDP1LMNA | |
| SCHEMBL43826 | 1.00 | BLM (0.62) | BLMTSHRNPSR1TDP1LMNA | |
| SCHEMBL10085813 | 1.00 | BLM (0.62) | BLMTSHRNPSR1TDP1LMNA | |
| SCHEMBL10786647 | 0.98 | BLM (0.61) | BLMTSHRNPSR1TDP1LMNA | |
| SCHEMBL20566321 | 0.85 | BLM (0.91) | BLMTSHRNPSR1TDP1LMNA | |
| SCHEMBL10456166 | 0.83 | BLM (0.59) | BLMTSHRNPSR1TDP1LMNA | |
| SCHEMBL9987910 | 0.82 | BLM (0.57) | BLMTSHRNPSR1TDP1LMNA | |
| SCHEMBL6395202 | 0.82 | BLM (0.57) | BLMTSHRNPSR1TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| CN-119757607-A | Biomarker, application, kit and identification method for identifying high-virulence klebsiella pneumoniae | 苏州木芮生物科技有限公司 | 2025-04-04 | — | — | CN | claimed |
| US-20250041183-A1 | AN AQUEOUS COMPOSITION FOR HAIR | KAO GERMANY GMBH (DE) | 2025-02-06 | — | — | US | claimed |
| WO-2025019764-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | MATTERWORKS INC (US) | 2025-01-23 | — | — | WO | claimed |
| US-20240369563-A1 | BIOMARKER COMBINATION FOR ASSESSING RISK OF ADENOMA AND COLORECTAL CANCER, AND USE THEREOF | HUMAN METABOLOMICS INSTITUTE, INC. (CN) | 2024-11-07 | — | — | US | claimed |
| EP-4447914-A1 | AN AQUEOUS COMPOSITION FOR HAIR | Kao Germany GmbH (DE) | 2024-10-23 | — | — | EP | claimed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | claimed |
| CN-118688333-A | Marker related to allergic rhinitis and kit thereof | 厦门市迈理奥科技有限公司 | 2024-09-24 | — | — | CN | claimed |
| US-5091171-A | Skin disorders | IGI, INC. | 1992-02-25 | — | — | US | claimed |
| EP-0036534-B1 | AN ORALLY ADMINISTRABLE DRUG FORM COMPRISING A BETA-LACTAM ANTIBIOTIC AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1987-09-23 | — | — | EP | claimed |
| EP-0031561-B1 | A RECTALLY ADMINISTERED SUPPOSITORY COMPRISING A DRUG AND AN ADJUVANT | MERCK & CO. INC. (US) | 1985-04-10 | — | — | EP | claimed |
| US-4470980-A | Method of increasing oral absorption of β-lactam antibiotics | INTERX RESEARCH CORP. (US) | 1984-09-11 | — | — | US | claimed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0035770-A2 | An orally administered drug form comprising a glycosidic antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-16 | — | — | EP | claimed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | claimed |
| US-4042329-A | Method and device for detecting cholesterol | BECTON, DICKINSON AND COMPANY (US) | 1977-08-16 | — | — | US | claimed |
| US-3964871-A | GLUCOSE OXIDASE, HORSERADISH PEROXIDASE | BECTON, DICKINSON AND COMPANY (US) | 1976-06-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041183-A1 | AN AQUEOUS COMPOSITION FOR HAIR | TYR, POLR1C, AHR | BLM 3161/4885TSHR 4265/4885NPSR1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.